Hyderabad: India Biotech’s factsheet on the coronavirus vaccine Covaxin advises pregnant or lactating women, in addition to those with high fever or bleeding disorders, not to take the antidote.
In the factsheet on Covaxin, the vaccine manufacturer, posted on its website, stated that the clinical efficacy of the vaccine is yet to be established and is being studied in Phase 3 clinical trials and therefore it is important to appreciate that Getting the vaccine is not another. Precautions related to COVID-19 should not be followed.
If you have any history of allergy, you should not get COVID-19 vaccine Covaxin from Bharat Biotech. High fever. Bleeding disorder or blood thinning.
Immune compromised or is a medication that affects your immune system. Are pregnant Are breastfeeding. Another COVID-19 vaccine has been found. Any other serious health issues as determined by the Immunization Officer / Officer overseeing vaccination according to the facts “.
The fact sheet asked people to inform the vaccine or the officer who supervised them before taking the vaccine. Bharat Biotech stated that in ongoing clinical trials Covaxin has been shown to induce immunity after two doses given four weeks.
Covaxin is a vaccine with approval for restricted use in emergency situations that can prevent COVID-19. The Fact Sheet states that the Central Licensing Authority has permitted the sale or distribution of antidotes for restricted use in emergency situations in the public interest.
The company stated that Covaxin is a highly pure and inactive two-dose SARS-COV-2 vaccine, manufactured in the Vero cell manufacturing platform with an excellent safety track record of over 300 million doses.
Covaxin is India’s fully indigenous COVID-19 vaccine developed in collaboration with the Indian Council of Medical Research and the National Institute of Virology. The inactivated vaccine is developed and manufactured with India’s Biotech BS3 (Bio-Safety Level 3) facility, one of its kind in the world.